Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.

Thakral P, Singla S, Yadav MP, Vasisht A, Sharma A, Gupta SK, Bal CS; Snehlata, Malhotra A.

Indian J Med Res. 2014 Apr;139(4):544-54.

2.

In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.

Forrer F, Chen J, Fani M, Powell P, Lohri A, Müller-Brand J, Moldenhauer G, Maecke HR.

Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1443-52. doi: 10.1007/s00259-009-1120-2. Epub 2009 Apr 7.

PMID:
19350237
3.

High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.

Weber T, Bötticher B, Mier W, Sauter M, Krämer S, Leotta K, Keller A, Schlegelmilch A, Grosse-Hovest L, Jäger D, Haberkorn U, Arndt MA, Krauss J.

Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):489-98. doi: 10.1007/s00259-015-3175-6. Epub 2015 Sep 4.

PMID:
26341366
4.

Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.

Gholipour N, Jalilian AR, Khalaj A, Johari-Daha F, Yavari K, Sabzevari O, Khanchi AR, Akhlaghi M.

Daru. 2014 Jul 29;22:58. doi: 10.1186/2008-2231-22-58.

5.

Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.

Vera DR, Eigner S, Beran M, Henke KE, Laznickova A, Laznicek M, Melichar F, Chinol M.

Cancer Biother Radiopharm. 2011 Jun;26(3):287-97. doi: 10.1089/cbr.2010.0916. Epub 2011 Jun 28.

PMID:
21711096
6.

Standardization of Procedures for the Preparation of (177)Lu- and (90)Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation.

Wojdowska W, Karczmarczyk U, Maurin M, Garnuszek P, Mikołajczak R.

Curr Radiopharm. 2015;8(1):62-8.

PMID:
25506704
7.

Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.

Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC.

J Nucl Med. 2004 Feb;45(2):327-37.

8.

Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability.

Cooper MS, Ma MT, Sunassee K, Shaw KP, Williams JD, Paul RL, Donnelly PS, Blower PJ.

Bioconjug Chem. 2012 May 16;23(5):1029-39. doi: 10.1021/bc300037w. Epub 2012 Apr 13.

9.

Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.

Grünberg J, Lindenblatt D, Dorrer H, Cohrs S, Zhernosekov K, Köster U, Türler A, Fischer E, Schibli R.

Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1907-15. doi: 10.1007/s00259-014-2798-3. Epub 2014 May 24.

PMID:
24859811
10.

Preparation & in vitro evaluation of ⁹⁰Y-DOTA-rituximab.

Kameswaran M, Pandey U, Dash A, Samuel G, Venkatesh M.

Indian J Med Res. 2016 Jan;143(1):57-65. doi: 10.4103/0971-5916.178593.

11.

In vitro cytotoxicity of low-dose-rate radioimmunotherapy by the alpha-emitting radioimmunoconjugate Thorium-227-DOTA-rituximab.

Dahle J, Krogh C, Melhus KB, Borrebaek J, Larsen RH, Kvinnsland Y.

Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):886-95. doi: 10.1016/j.ijrobp.2009.04.062. Epub 2009 Aug 11.

PMID:
19679402
12.

Optimization of 90 Y-antiCD20 preparation for radioimmunotherapy.

Gholipour N, Vakili A, Radfar E, Jalilian AR, Bahrami-Samani A, Shirvani-Arani S, Ghannadi-Maragheh M.

J Cancer Res Ther. 2013 Apr-Jun;9(2):199-204. doi: 10.4103/0973-1482.113350.

13.

Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma.

Yadav MP, Singla S, Thakral P, Ballal S, Bal C.

Nucl Med Commun. 2016 Jul;37(7):735-42. doi: 10.1097/MNM.0000000000000501.

PMID:
26974315
14.

Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL).

Kang HJ, Lee SS, Kim KM, Choi TH, Cheon GJ, Kim WS, Suh C, Yang SH, Lim SM.

Asia Pac J Clin Oncol. 2011 Jun;7(2):136-45. doi: 10.1111/j.1743-7563.2011.01393.x.

PMID:
21585693
15.

Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab.

Forrer F, Oechslin-Oberholzer C, Campana B, Maecke H, Mueller-Brand J, Lohri A.

Q J Nucl Med Mol Imaging. 2012 Dec;56(6):544-50.

16.

Synthesis and Preclinical Evaluation of (177)Lu-CHX-A"-DTPA-Rituximab as a Radioimmunotherapeutic Agent for Non-Hodgkin's Lymphoma.

Kameswaran M, Pandey U, Dhakan C, Pathak K, Gota V, Vimalnath KV, Dash A, Samuel G.

Cancer Biother Radiopharm. 2015 Aug;30(6):240-6. doi: 10.1089/cbr.2015.1836. Epub 2015 Jun 11.

PMID:
26066665
17.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
18.

Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.

Bhusari P, Vatsa R, Singh G, Parmar M, Bal A, Dhawan DK, Mittal BR, Shukla J.

Int J Cancer. 2017 Feb 15;140(4):938-947. doi: 10.1002/ijc.30500. Epub 2016 Nov 18.

PMID:
27813061
19.

Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.

Chinn PC, Leonard JE, Rosenberg J, Hanna N, Anderson DR.

Int J Oncol. 1999 Nov;15(5):1017-25.

PMID:
10536187
20.

Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy.

Dahle J, Borrebaek J, Melhus KB, Bruland OS, Salberg G, Olsen DR, Larsen RH.

Nucl Med Biol. 2006 Feb;33(2):271-9.

PMID:
16546683

Supplemental Content

Support Center